This article is more than 5 years old. Information may no longer be current.

FDA requires more information from Avedro regarding cross-linking treatment

Avedro received a complete response letter from the U.S. Food and Drug Administration that identified several areas in which its new drug application for its riboflavin ophthalmic solution/KXL System needs additional information, according to a press release.

Avedro CEO David Muller, MD, PhD, said the company will work with the FDA to resolve these issues. He also noted the company does not know how long the process will take.

The riboflavin ophthalmic solution/KXL System is under investigation for the treatment of keratoconus and corneal ectasia.